{
    "title": "113_hr3303",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Sensible Oversight for Technology \nwhich Advances Regulatory Efficiency Act of 2013'' or the ``SOFTWARE \nAct of 2013''.\n\nSEC. 2. MEDICAL SOFTWARE.\n\n    (a) Definition of Medical Software.--Section 201 of the Federal \nFood, Drug, and Cosmetic Act (21 U.S.C. 321) is amended by adding at \nthe end the following:\n    ``(ss) The term `medical software' means software that is intended \nfor human or animal use and--\n            ``(1)(A) is intended to be marketed to directly change the \n        structure or any function of the body of man or other animals; \n        or\n            ``(B) is intended to be marketed for use by consumers and \n        makes recommendations for clinical action that--\n                    ``(i) includes the use of a drug, device, or \n                procedure to cure or treat a disease or other condition \n                without requiring the involvement of a health care \n                provider; and\n                    ``(ii) if followed, would change the structure or \n                any function of the body of man or other animals;\n            ``(2) is not software whose primary purpose is integral to \n        the functioning of a drug or device; and\n            ``(3) is not a component of a device.''.\n    (b) Regulation.--Subchapter A of chapter V of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by adding at \nthe end the following:\n\n``SEC. 524B. MEDICAL SOFTWARE.\n\n    ``(a) In General.--The provisions of this Act shall apply with \nrespect to medical software to the same extent and in the same manner \nas such provisions apply with respect to devices.\n    ``(b) Delegation.--The Secretary shall delegate primary \njurisdiction for regulating medical software to the center at the Food \nand Drug Administration charged with regulating devices.''.\n\nSEC. 3. CLINICAL SOFTWARE AND HEALTH SOFTWARE.\n\n    (a) Definitions.--Section 201 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 321), as amended by section 2(a), is further \namended by adding at the end the following:\n    ``(tt)(1) The term `clinical software' means clinical decision \nsupport software or other software (including any associated hardware \nand process dependencies) intended for human or animal use that--\n            ``(A) captures, analyzes, changes, or presents patient or \n        population clinical data or information and may recommend \n        courses of clinical action, but does not directly change the \n        structure or any function of the body of man or other animals; \n        and\n            ``(B) is intended to be marketed for use only by a health \n        care provider in a health care setting.\n    ``(2) The term `health software' means software (including any \nassociated hardware and process dependencies) that is not medical \nsoftware or clinical software and--\n            ``(A) that captures, analyzes, changes, or presents patient \n        or population clinical data or information;\n            ``(B) that supports administrative or operational aspects \n        of health care and is not used in the direct delivery of \n        patient care; or\n            ``(C) whose primary purpose is to act as a platform for a \n        secondary software, to run or act as a mechanism for \n        connectivity, or to store data.''.\n    (b) Prohibition.--Subchapter A of chapter V of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 351 et seq.), as amended by section \n2(b), is further amended by adding at the end the following:\n\n``SEC. 524C. CLINICAL SOFTWARE AND HEALTH SOFTWARE.\n\n    ``Clinical software and health software shall not be subject to \nregulation under this Act.''.\n    (c) Sense of Congress.--It is the sense of the Congress that--\n            (1) clinical software and health software (as defined in \n        section 201(tt) of the Federal Food, Drug, and Cosmetic Act, as \n        added by subsection (a))--\n                    (A) advance the goals of enhanced patient safety \n                and continued innovation;\n                    (B) hold much promise to lower costs and improve \n                the health of patients; and\n                    (C) can improve the quality and efficacy of health \n                care provider services; and\n            (2) the President and the Congress should work together to \n        develop and enact legislation that establishes a risk-based \n        regulatory framework for such clinical software and health \n        software that reduces regulatory burdens, promotes patient \n        safety, and fosters innovation.\n\nSEC. 4. EXCLUSION FROM DEFINITION OF DEVICE.\n\n    Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 321) is amended--\n            (1) in paragraph (2), by striking ``or other animals, or'' \n        and inserting ``or other animals,'';\n            (2) in paragraph (3), by striking ``and''; and\n            (3) by inserting after paragraph (3) the following new \n        paragraphs:\n            ``(4) is not medical software, or\n            ``(5) is not clinical software or health software, and''."
}